A Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum Microbiota? (CP101) in Subjects with Recurrence of Clostridium difficile Infection (2/22/2018 version 3)
This Study is
No Longer Enrolling
This is a double-blind, placebo-controlled, parallel-arm, multicenter study comparing the safety, tolerability, and efficacy of CP101 treatment relative to placebo in adults with previously treated recurrent CDI. Subjects who are experiencing recurrent CDI will undergo screening procedures. Subjects who meet eligibility criteria will be randomized to study drug. Approximately 200 subjects (100 subjects per treatment group) will be randomized in a 1:1 ratio to receive CP101 (6 1011 bacteria) or placebo. The treatment duration will be 1 day, including active drug (CP101) and placebo. Subjects will be monitored for recurrence of CDI, safety, and tolerability for 24 weeks following Randomization. The primary efficacy and safety endpoints will be evaluated at 8 weeks post-treatment, and all subjects will continue to be followed for an additional 16 weeks for safety and recurrence of CDI. To qualify for the study, subjects must be experiencing recurrent CDI defined as: a) 3 episodes of CDI, with 2 episodes occurring within the previous 12 months (inclusive of the current episode); OR b) 2 episodes of CDI occurring within the previous 6 months (inclusive of the current episode) AND 65 years of age or older. Additionally, to qualify, recurrent CDI subjects must have received standard-of-care CDI antibiotics for the most recent CDI episode (for 10-21 days, with exact duration, antibiotic type, and dose at the discretion of the Investigator) and have an adequate clinical response, defined as 3 unformed stools in 24 hours for 2 or more consecutive days immediately prior to Randomization.
MoreAdult
Recurrent CDI* as defined by: a)  3 episodes of CDI, with 2 episodes occurring within the previous 12 months (inclusive of the current episode); OR b) 2 episodes of CDI occurring within the previous 6 months (inclusive of the current episode) AND 65 years of age or older; Has received a course of standard-of-care CDI antibiotics for the most recent CDI episode (for 10-21 days, with exact duration, antibiotic type, and dose at the discretion of the Investigator); and d) Has an adequate clinical response, defined as  3 unformed stools in 24 hours for 2 or more consecutive days immediately prior to Randomization;
Randomization (Day 1) Inclusion Criteria: 1. An outpatient prior to Randomization; a) NOTE: Subject may be enrolled while an inpatient in an acute care facility, but must be discharged prior to Randomization on Day 1. Subjects residing in an assisted living center, long-term care facility, or rehabilitation center may be randomized; 2. Has received a course of standard-of-care CDI antibiotics for the most recent CDI episode (for 10-21 days, with exact duration, antibiotic type, and dose at the discretion of the Investigator); 3. Has an adequate clinical response, defined as 3 unformed stools in 24 hours for 2 or more consecutive days immediately prior to Randomization; and 4. Subject has completed a washout (i.e., a minimum of 2 and a maximum of 4 days after cessation of standard-of-care CDI antibiotics).
Treatment
Outpatient CTRC
University of Colorado Hospital
Protocol Number: 18-1166
More information available at ClinicalTrials.gov: NCT03497806
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers